| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
66,230,000 |
| Market
Cap: |
4.11(M) |
| Last
Volume: |
362,100 |
Avg
Vol: |
361,089 |
| 52
Week Range: |
$0.062 - $0.062 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  O'connor Daniel |
Chief Executive Officer |
• – – |
2015-11-30 |
4 |
D |
$12.07 |
$1,605 |
D/D |
(133) |
332,190 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-11-30 |
4 |
A |
$12.07 |
$7,121 |
D/D |
590 |
332,323 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-11-30 |
4 |
D |
$12.07 |
$217 |
D/D |
(18) |
166,118 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-11-30 |
4 |
A |
$12.07 |
$1,304 |
D/D |
108 |
166,136 |
|
- |
|
| Patton James P |
Director |
– • – |
2015-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,459 |
211,749 |
|
- |
|
| Sidransky David |
Director |
– • – |
2015-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,744 |
103,163 |
|
- |
|
| Ridge Thomas J |
Director |
– • – |
2015-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,430 |
19,306 |
|
- |
|
| Khleif Samir N |
Director |
– • – |
2015-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,430 |
69,587 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-10-30 |
4 |
S |
$12.26 |
$102,371 |
D/D |
(8,350) |
331,733 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-10-30 |
4 |
D |
$11.09 |
$3,560 |
D/D |
(321) |
340,083 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-10-30 |
4 |
A |
$11.09 |
$7,109 |
D/D |
641 |
340,404 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2015-10-30 |
4 |
D |
$11.09 |
$333 |
D/D |
(30) |
94,517 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2015-10-30 |
4 |
A |
$11.09 |
$1,641 |
D/D |
148 |
94,547 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-10-30 |
4 |
D |
$11.09 |
$233 |
D/D |
(21) |
166,028 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-10-30 |
4 |
A |
$11.09 |
$1,298 |
D/D |
117 |
166,049 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-10-30 |
4 |
D |
$11.09 |
$399 |
D/D |
(36) |
119,961 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-10-30 |
4 |
A |
$11.09 |
$1,952 |
D/D |
176 |
119,997 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-10-30 |
4 |
S |
$12.26 |
$35,149 |
D/D |
(2,867) |
133,099 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-10-30 |
4 |
D |
$11.09 |
$843 |
D/D |
(76) |
135,966 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-10-30 |
4 |
A |
$11.09 |
$1,952 |
D/D |
176 |
136,042 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-10-26 |
4 |
S |
$11.63 |
$223,657 |
D/D |
(19,231) |
119,821 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-10-20 |
4 |
S |
$10.08 |
$247,827 |
D/D |
(24,586) |
165,932 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-09-30 |
4 |
D |
$10.23 |
$1,627 |
D/D |
(159) |
339,763 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-09-30 |
4 |
A |
$10.23 |
$7,110 |
D/D |
695 |
339,922 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2015-09-30 |
4 |
D |
$10.23 |
$317 |
D/D |
(31) |
94,399 |
|
- |
|
465 Records found
|
|
Page 10 of 19 |
|
|
